Evidence map›Paper›PMID 37768074›Full record

Trial reportAlzheimer's & dementia : the journal of the Alzheimer's Association2024

A multidomain intervention against cognitive decline in an at-risk-population in Germany: Results from the cluster-randomized AgeWell.de trial.

Andrea E Zülke, Alexander Pabst, Melanie Luppa, Susanne Roehr, Hanna Seidling, Anke Oey, Maria Isabel Cardona, Iris Blotenberg, Alexander Bauer, Solveig Weise and 15 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 3 pooled it
16.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Does lifestyle intervention lower clinically significant cognitive impairment risk?Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Baseline cognition and demographic, lifestyle, and cardiovascular risk factors in US POINTER.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 12 institutions in 3 countries.

Andrea E ZülkeInstitute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, Leipzig, Germany.
Alexander PabstInstitute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, Leipzig, Germany.
Melanie LuppaInstitute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, Leipzig, Germany.
Susanne RoehrInstitute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, Leipzig, Germany.
Hanna SeidlingDepartment of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
Anke OeyInstitute for General Practice, Work Group Medical Statistics and IT-Infrastructure, Hannover Medical School, Hannover, Germany.
Maria Isabel CardonaGerman Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Greifswald, Germany.
Iris BlotenbergGerman Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Greifswald, Germany.
Alexander BauerInstitute of General Practice and Family Medicine, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Solveig WeiseInstitute of General Practice and Family Medicine, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Isabel ZöllingerInstitute of General Practice/Family Medicine, University Hospital of LMU Munich, Munich, Germany.
Linda SanftenbergInstitute of General Practice/Family Medicine, University Hospital of LMU Munich, Munich, Germany.
Christian BrettschneiderUniversity Medical Center Hamburg-Eppendorf, Department of Health Economics and Health Service Research, Hamburg, Germany.
Juliane DöhringInstitute of General Practice, University of Kiel, Kiel, Germany.
Laura LundenInstitute of General Practice, University of Kiel, Kiel, Germany.
David CzockDepartment of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
Walter E HaefeliDepartment of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
Birgitt WieseInstitute for General Practice, Work Group Medical Statistics and IT-Infrastructure, Hannover Medical School, Hannover, Germany.
Wolfgang HoffmannGerman Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Greifswald, Germany.
Thomas FreseInstitute of General Practice and Family Medicine, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Jochen GensichenInstitute of General Practice/Family Medicine, University Hospital of LMU Munich, Munich, Germany.
Hans-Helmut KönigUniversity Medical Center Hamburg-Eppendorf, Department of Health Economics and Health Service Research, Hamburg, Germany.
Hanna KaduszkiewiczInstitute of General Practice, University of Kiel, Kiel, Germany.
Jochen René ThyrianGerman Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Greifswald, Germany.
Steffi G Riedel-HellerInstitute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, Leipzig, Germany.
Leipzig University · DEKiel University · DEMartin Luther University Halle-Wittenberg · DEGerman Center for Neurodegenerative Diseases · DEHeidelberg University · DELMU Klinikum · DEMedizinische Hochschule Hannover · DEUniversitätsmedizin Greifswald · DEUniversity Medical Center Hamburg-Eppendorf · DELudwig-Maximilians-Universität München · DEMassey University · NZUniversity Hospital Heidelberg · DE

Funding

German Federal Ministry for Education and Research 01GL1704AGerman Federal Ministry for Education and Research 01GL1704BGerman Federal Ministry for Education and Research 01GL1704CGerman Federal Ministry for Education and Research 01GL1704DGerman Federal Ministry for Education and Research 01GL1704EGerman Federal Ministry for Education and Research 01GL1704F
6 · The paper itself

Abstract

introductionWe investigated the effectiveness of a multidomain intervention to preserve cognitive function in older adults at risk for dementia in Germany in a cluster-randomized trial.

methodsIndividuals with a Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) risk score ≥ 9 aged 60 to 77 years were recruited. After randomization of their general practitioner (GP), patients received a multidomain intervention (including optimization of nutrition and medication, and physical, social, and cognitive activity) or general health advice and GP treatment as usual over 24 months. Primary outcome was global cognitive performance (composite z score, based on domain-specific neuropsychological tests).

resultsOf 1030 participants at baseline, n = 819 completed the 24-month follow-up assessment. No differences regarding global cognitive performance (average marginal effect = 0.010, 95% confidence interval: -0.113, 0.133) were found between groups at follow-up. Perceived restrictions in intervention conduct by the COVID-19 pandemic did not impact intervention effectiveness. DISCUSSION: The intervention did not improve global cognitive performance. HIGHLIGHTS: Overall, no intervention effects on global cognitive performance were detected. The multidomain intervention improved health-related quality of life in the total sample. In women, the multidomain intervention reduced depressive symptoms. The intervention was completed during the COVID-19 pandemic.

Indexed as

Cognitive DysfunctionCOVID-19DementiaAgedFemaleHumansPandemicsQuality of LifeRisk Factorscognitive functiondementialifestylepreventionrandomized controlled trial

Identifiers

PMID37768074
PMCPMC10917033
OpenAlexW4387115297

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.